Antimicrobial Resistance (AMR) is one of the most urgent health challenges today, making infections harder—and sometimes impossible—to treat. This episode of Fixed on ESG explores what AMR is, why it matters, and its wide-ranging impact on health systems and the global economy.

We also highlight the science behind resistance, why innovation in diagnostics, vaccines, and stewardship is critical, and what investors should consider as AMR drives rising healthcare costs, regulatory pressures, and opportunities in new technologies.

PGIM's Birgit Lundem Jakobsen, ESG Specialist, hosts this discussion with Amish Acharya, Senior Scientific and Clinical Advisor from the Fleming Initiative.

Recorded on January 20, 2026.

COP30 took place in Belém, Brazil, at the heart of the Amazon, setting the stage for high-stakes climate negotiations amid one of the planet's most critical ecosystems. This episode of Fixed on ESG examines the summit's defining outcomes: the formal acknowledgment that the 1.5°C target is no longer attainable without overshoot, debates over fossil fuel phase-outs, and the shifting balance of influence as emerging markets assert a stronger role amid the absence of U.S. leadership.

We also explore new climate finance pledges, adaptation funding, and the launch of the Tropical Forests Forever initiative, alongside the EU's trade measures and revised emissions targets—analyzing how these developments could shape the trajectory of global climate action.

PGIM's John Ploeg, CFA, Co-Head of Fixed Income ESG Research, hosts this discussion with Roma Wilkinson, ESG Specialist.

Recorded on December 9, 2025.

Access to medicine is a vital issue at the crossroads of global health issue, corporate responsibility, and ESG investing. Join us as we unpack barriers to equitable access, explore how pharmaceutical companies and ESG-focused investors are addressing these challenges, the emergence of patient reach is as a measure of progress, and how improvements in reporting can align access initiatives with business models to drive both sustainable growth and social impact.

Birgit Lundem Jakobsen, ESG Specialist at PGIM, hosts this discussion with Bram Wagner, Investor Engagement Lead for the Access to Medicine Foundation, and Hank Balbirer, CFA, U.S. Investment Grade Senior Credit Research Analyst at PGIM.

Recorded on November 5, 2025.